Latest International Market Expansion News

Advanced Braking Technology (ASX: ABV) posted a record $6.2 million in product sales for Q4 FY26, lifting full-year revenue 22.7% to $23.5 million. The company’s autonomous BRAKEiQ system advanced key milestones as international engagement expanded.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Smart Parking Limited grew its ANPR sites by 17% in Q3 FY26 and increased parking breach notices by 19%, leveraging acquisitions and AI technology to expand across Europe and New Zealand.

Advanced Braking Technology Ltd (ASX: ABV) reported a 28% jump in product sales revenue to $6 million for Q3 FY26, driven by strong aftermarket sales and international market traction. The company also advanced certification of its autonomous BRAKEiQ system, targeting FY27 adoption.

SPC Global Holdings Limited reported continued improvement in Q3 FY26, with net sales revenue and normalised EBITDA on track to meet full-year guidance. The company is progressing with its Mill Park facility closure and expanding its international footprint, particularly in Asia.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.